Innovent Biologics' BTK inhibitor Jaypirca has received approval from China's NMPA for the treatment of relapsed/refractory CLL and SLL, further enriching its oncology product portfolio.
This approval marks a significant milestone in Innovent Biologics' development journey, signifying the company's further expansion of its drug pipeline in China, particularly in next-generation BTK inhibitors within the oncology field. The drug opens up new therapeutic avenues for patient populations with limited treatment options, potentially changing the standard of care for relapsed/refractory CLL and SLL, and enhancing Innovent Biologics' competitiveness in the highly competitive hematologic oncology market.
NMPA approves Jaypirca for the treatment of adult relapsed/refractory CLL and SLL.
The approval is based on the Phase III BRUIN study, which showed significant advantages in progression-free survival.
Jaypirca offers a new treatment option for patients who have previously failed BTK inhibitor therapy.
Jaypirca offers a new treatment option for patients who have previously failed BTK inhibitor therapy.
Innovent Biologics further strengthens its market position in the field of hematologic oncology in China.
Sign in to save notes on signals.
登录